ZIA BC 011413 (ZIA) | |||
---|---|---|---|
Title | Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Kochenderfer, James | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $167,778 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2016 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Gene Therapy (100.0%) |
Non Hodgkins Lymphoma (100.0%) | ||
Research Type | |||
Technology and/or Marker Testing in a Clinical Setting Systemic Therapies - Discovery and Development |
|||
Abstract | |||
This project is evaluating a novel fully-human anti-CD19 CAR. The rationale for a fully-human CAR is to avoid recipient anti-CAR immune responses that probably target most CARs in current clinical use because most CARs contain murine components. The new fully-human CAR was invented by James Kochenderfer, and all preclinical work on this CAR was performed in his laboratory. This project is a combination of a clinical trial of infusions of autologous anti-CD19 chimeric-antigen-receptor-transduced T cells and laboratory experiments performed on cells obtained from patients that received infusions of the chimeric-antigen-receptor-transduced T cells. We have initiated a new clinical trial in the past year that The most prominent toxicity were hypotension and neurological toxicity. These results demonstrate that CAR-expressing T cells can specifically eliminate targeted cells and cause significant cytokine-mediated toxicity in humans. Current efforts are aimed at evaluating low-dose chemotherapy regimens administered before anti-CD19 CAR T cells. We initiated a clinical trial of autologous T cells expressing this novel fully-human CAR in January of 2016. We have treated 9 patients to date. Seven patients are evaluable for response, and 6 of the 7 patients have had objective anti-lymphoma responses. |